LY-2940094
From Infogalactic: the planetary knowledge core
| Clinical data | |
|---|---|
| Routes of administration |
Oral |
LY-2940094 is a potent and selective nociceptin receptor antagonist which is under investigation by Eli Lilly for the treatment of major depressive disorder and alcohol dependence.[1][2] It has demonstrated proof-of-concept clinical efficacy for depression.[3] As of 2015, it is in phase II clinical trials for both of the aforementioned indications.[1][2] Its chemical structure has yet to be published.[1]
See also
References
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Categories:
- Infobox drug articles without a structure image
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Nociceptin receptor antagonists
- Synthetic opioids
- Nervous system drug stubs
